argenx's Forte acquisition delivers coeliac trial win

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

FDA fast-tracks Teva's coeliac disease treatment

Teva gets fast-track status from the FDA for a coeliac disease drug with a mechanism that has proved tough to crack.

Equillium triples clinical pipeline with $329m Bioniz takeov...

Equillium has announced another bolt-on deal to expand its pipeline tripling the size of its clinical pipeline to three drug candidates via a $329 million agreement to acquire Bioniz Therap

Takeda buys US biotech PvP Biologics for $330 million

Takeda has bought US biotech PvP Biologics for $330 million, adding a potential new form of therapy for coeliac disease to its pipeline.

Takeda buys coeliac drug licence from COUR Pharmaceuticals

Takeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced supportive phase 2a trial data.

GSK buys Avalon-partnered Sitari and its coeliac drug